SEC FORM 3

SEC FORM 3SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

de Boer Daniel Anton

(Last)

(First)

(Middle)

PROQR THERAPEUTICS N.V.

ZERNIKEDREEF 9

(Street)

LEIDEN

2333 CK

(City)

(State)

(Zip)

NETHERLANDS

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
ProQR Therapeutics N.V. [ PRQR ]

3a. Foreign Trading Symbol
[N/A]

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Executive Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Share Option (Right to Buy)	⁽¹⁾	12/31/2026	Ordinary Shares	239,717	$4.9	D
Share Option (Right to Buy)	⁽¹⁾	12/31/2027	Ordinary Shares	379,285	$3.3	D
Share Option (Right to Buy)	⁽¹⁾	12/31/2028	Ordinary Shares	253,192	$15.78	D
Share Option (Right to Buy)	⁽¹⁾	12/31/2029	Ordinary Shares	395,561	$9.91	D
Share Option (Right to Buy)	⁽¹⁾	12/31/2030	Ordinary Shares	442,279	$4.2	D
Share Option (Right to Buy)	⁽¹⁾	02/29/2032	Ordinary Shares	450,051	$1.02	D
Share Option (Right to Buy)	⁽²⁾	05/31/2032	Ordinary Shares	1,200,000	$0.66	D
Share Option (Right to Buy)	⁽³⁾	12/31/2032	Ordinary Shares	442,182	$3.41	D
Share Option (Right to Buy)	⁽⁴⁾	12/31/2033	Ordinary Shares	479,171	$1.98	D
Share Option (Right to Buy)	⁽⁵⁾	12/31/2034	Ordinary Shares	463,587	$2.65	D
Share Option (Right to Buy)	⁽⁶⁾	09/22/2035	Ordinary Shares	1,400,000	$2.16	D
Share Option (Right to Buy)	⁽⁷⁾	12/31/2035	Ordinary Shares	595,644	$2.02	D

Explanation of Responses:

1. Fully vested.

2. 25% of the shares subject to such option vest and become exercisable on June 1, 2023, and the remaining 75% vest and become exercisable in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.

3. 25% of the shares subject to such option vest and become exercisable on January 1, 2024, and the remaining 75% vest and become exercisable in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.

4. 25% of the shares subject to such option vest and become exercisable on January 1, 2025, and the remaining 75% vest and become exercisable in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.

5. 25% of the shares subject to such option vest and become exercisable on January 1, 2026, and the remaining 75% vest and become exercisable in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.

6. 25% of the shares subject to such option vest and become exercisable on September 23, 2026, and the remaining 75% vest and become exercisable in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.

7. 25% of the shares subject to such option vest and become exercisable on January 1, 2027, and the remaining 75% vest and become exercisable in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Pieter Erik de Ridders, Attorney-in-Fact	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

SEC Form 3 filed by new insider De Boer Daniel Anton